Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipidemia Clear all
Active, not recruiting Not applicable Interventional

Onco-primary Care Networking to Support TEAM-based Care

NCT04258813
View directory record Official record
Conditions
Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
Interventions
iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 79 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Patient-Spouse Intervention for Self-Managing High Cholesterol

NCT00321789
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
spouse-assisted intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Policosanol for the Treatment of Hypercholesterolemia

NCT00255216
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Policosanol supplement (oral capsule) vs. placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT04720534
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
ARO-APOC3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084
View directory record Official record
Conditions
Familial Chylomicronemia
Interventions
Plozasiran, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.

NCT00755352
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
pravastatin tablets and Welchol tablets, pravastatin tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
15
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 21, 2026, 9:53 AM EDT
Not listed Phase 4 Interventional

Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

NCT00972829
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Rosuvastatin, Ezetimibe
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1

NCT03958734
View directory record Official record
Conditions
Cardiovascular Risk Factor, Lipemia
Interventions
High-fat meal
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 30 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 21, 2026, 9:53 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Anti-inflammatory Effects of Simvastatin

NCT04638400
View directory record Official record
Conditions
Inflammation, Atherosclerosis, Hypercholesterolemia
Interventions
Simvastatin 40mg, Ezetimibe 10mg
Drug
Lead sponsor
paresh Dandona
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 21, 2026, 9:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Daily Inclusion of Eggs in a Heart-Healthful Dietary Pattern in Hyperlipidemic Adults

NCT05807334
View directory record Official record
Conditions
Hyperlipidemias
Interventions
DASH eating plan with eggs, DASH eating plan without eggs
Other
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 21, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional

Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

NCT00080132
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
implitapide
Drug
Lead sponsor
Medical Research Laboratories International
Industry
Eligibility
8 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

NCT02992301
View directory record Official record
Conditions
Atherosclerosis, Hyperlipidemia
Interventions
Alirocumab
Drug
Lead sponsor
Westside Medical Associates of Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations

NCT00688857
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Diazoxide choline
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 21, 2026, 9:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Dietary Sources of Lysophospholipids

NCT02952638
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor, Hyperlipidemia
Interventions
Not listed
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 21, 2026, 9:53 AM EDT
Available No phase listed Expanded access

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

NCT06796426
View directory record Official record
Conditions
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Interventions
Plozasiran
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
15 Years and older
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Recruiting Not applicable Interventional

FELLAShip to Better Health

NCT07220213
View directory record Official record
Conditions
High Blood Glucose, High Cholesterol, High Cholesterol/Hyperlipidemia, Blood Sugar; High, Obesity & Overweight, Diabetes Type 2
Interventions
FELLAship
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 21, 2026, 9:53 AM EDT
Not yet recruiting Not applicable Interventional

Community Intervention to Improve CVD Risk Factor Control in Young American Indians

NCT06230705
View directory record Official record
Conditions
Cholesterol, Elevated, Diabetes Mellitus
Interventions
Guided management, Self management
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

NCT01350141
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, PF-04950615 (RN316)
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Clinical Inertia in Diabetes Care

NCT00272402
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions
Cognitive Behavioral Intervention, Office System Redesign Intervention
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 21, 2026, 9:53 AM EDT
Withdrawn No phase listed Observational

Genetic Influence on Statin Pharmacodynamics

NCT01569854
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

NCT03175367
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 21, 2026, 9:53 AM EDT